Published in Br J Cancer on February 07, 2012
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer (2014) 1.08
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget (2015) 1.01
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. Br J Cancer (2013) 0.99
Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther (2014) 0.94
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget (2015) 0.93
Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer. BMC Cancer (2014) 0.92
Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep (2015) 0.89
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. Biomed Res Int (2016) 0.85
Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. PLoS One (2015) 0.84
Lactate Dehydrogenase Is an Important Prognostic Indicator for Hepatocellular Carcinoma after Partial Hepatectomy. Transl Oncol (2015) 0.83
Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer (2015) 0.82
Increased LDH5 expression is associated with lymph node metastasis and outcome in oral squamous cell carcinoma. Clin Exp Metastasis (2012) 0.81
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. Cancer Manag Res (2015) 0.81
The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis. BMC Cancer (2016) 0.80
Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol (2013) 0.80
The clinicopathologic importance of serum lactic dehydrogenase in patients with gastric cancer. Dis Markers (2014) 0.79
Longterm effects of palliative local treatment of incurable metastatic lesions in colorectal cancer patients. Oncotarget (2016) 0.79
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol (2015) 0.78
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Sci Rep (2016) 0.78
Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer. Onco Targets Ther (2015) 0.78
Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget (2016) 0.78
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. Br J Cancer (2017) 0.77
Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients. BMC Cancer (2017) 0.77
Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis. Transl Oncol (2017) 0.75
Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. J Cancer (2016) 0.75
Varying postresection lactate dehydrogenase with overall survival of early stage pancreatic cancer patients: A retrospective study. Medicine (Baltimore) (2017) 0.75
Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms. Oncotarget (2016) 0.75
The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosis. J Gastrointest Oncol (2016) 0.75
Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases. J Surg Oncol (2016) 0.75
Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy. Sci Rep (2017) 0.75
Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area. Oncotarget (2016) 0.75
Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria. J Cancer Res Clin Oncol (2017) 0.75
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. ESMO Open (2017) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol (2003) 12.82
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2001) 2.59
Activation of the HIF pathway in cancer. Curr Opin Genet Dev (2001) 2.38
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol (2011) 2.05
Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. J Clin Oncol (2006) 1.74
Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis (2005) 1.71
Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol (2003) 1.47
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res (2011) 1.46
Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol (2001) 1.36
Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics (2007) 1.23
Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol (2010) 1.14
Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol (2001) 1.04
Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynaecol Oncol (2001) 0.90
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol (2008) 4.27
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol (2006) 2.19
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol (2012) 1.78
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer (2009) 1.46
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol (2007) 1.44
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Indirect evidence for transfusion role in conditioning hepatitis C virus prevalence among dialysis patients. Nephron (1991) 1.42
[Paraneoplastic syndromes: a review]. Clin Ter (2006) 1.39
Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol (2003) 1.36
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol (2012) 1.28
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer (2012) 1.21
Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol (2008) 1.19
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer (2013) 1.15
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol (2000) 1.13
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer (2007) 1.07
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol (2007) 1.06
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer (2013) 1.05
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer (2011) 1.04
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Ann Oncol (2004) 1.04
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol (2009) 1.02
KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann Oncol (2008) 1.01
Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma. J Clin Ultrasound (2001) 0.98
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Ann Oncol (2005) 0.97
Novel therapeutic approaches to cancer patients with bone metastasis. Crit Rev Oncol Hematol (2001) 0.97
HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol (2002) 0.96
Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study. J Clin Endocrinol Metab (2012) 0.95
Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br J Cancer (2006) 0.94
An intronic mutation in MLH1 associated with familial colon and breast cancer. Fam Cancer (2011) 0.93
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Ann Oncol (2009) 0.93
Survival and quality of life after intensive care. Intensive Care Med (1996) 0.92
Analgesia, sedation, and memory of intensive care. J Crit Care (2001) 0.92
Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. Eur Rev Med Pharmacol Sci (2010) 0.92
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol (2008) 0.91
Immunohistochemical telomeric-repeat binding factor-1 expression in gastrointestinal tumors. Oncol Rep (2000) 0.88
Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. Br J Cancer (2007) 0.86
Thyroid function in Fabry disease before and after enzyme replacement therapy. Minerva Endocrinol (2011) 0.85
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Support Care Cancer (2015) 0.85
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma. Support Care Cancer (2014) 0.85
Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade? Dig Liver Dis (2003) 0.84
Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer (2005) 0.84
[The empty sella syndrome. Clinical, radiological and endocrinologic analysis in 20 cases]. Minerva Endocrinol (1989) 0.83
Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study. Ann Oncol (1999) 0.83
Effectiveness of the CRCAPRO program in identifying patients suspected for HNPCC. Clin Genet (2007) 0.82
Thyroid diseases in elderly. Minerva Endocrinol (2011) 0.81
Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. Crit Rev Oncol Hematol (2001) 0.81
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. Br J Cancer (2003) 0.81
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer (2006) 0.81
Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. Br J Cancer (2005) 0.81
Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab (1994) 0.80
Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. Anticancer Res (2012) 0.80
Structural features of model glycopeptides in solution and in membrane phase: a spectroscopic and molecular mechanics investigation. Biopolymers (2002) 0.80
Increased VEGF165 expression in HCT116 colon cancer cells after transient transfection with a GFP vector encoding HIF-1 gene. J Exp Clin Cancer Res (2007) 0.80
Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Ann Oncol (2006) 0.80
Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy. Expert Rev Anticancer Ther (2001) 0.80
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. Ann Oncol (2010) 0.79
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) (2014) 0.79
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. Prostate Cancer Prostatic Dis (2013) 0.79
Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer. BMC Cancer (2001) 0.79
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. Br J Cancer (1996) 0.78
Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. Eur J Cancer (2003) 0.78
In-vacuum optical isolation changes by heating in a Faraday isolator. Appl Opt (2008) 0.78
Nerve growth factor receptor immunoreactivity in breast cancer patients. Cancer Invest (2001) 0.77
Phase II trial of 13-cis retinoic acid plus interferon-alpha in advanced squamous cell carcinoma of head and neck, refractory to chemotherapy. Ann Oncol (1996) 0.77
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. Oncology (2005) 0.76
Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis. Eur J Vasc Endovasc Surg (2002) 0.76
Docetaxel chemotherapy for pancreatic cancer: Do results support certainty? Italian Group for the Study of Gastrointestinal Tract Carcinomas. J Clin Oncol (2000) 0.76